PRTA — Prothena Corporation plc

Prothena Corporation plc (PRTA) is a biotechnology company listed on NASDAQ. It is led by Gene G. Kinney Ph.D., based in 77 Sir John Rogerson?s Quay, Dublin, Ireland, D02 VK60, with about 67 employees. Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease. In addition, it develops discovery- and late-preclinical-stage programs include TDP-43 CYTOPE for the treatment of amyotrophic lateral sclerosis; PRX012, a next-generation anti-Aß antibody which is in phase 1 clinical trial to treat Alzheimer's disease; and PRX012-TfR, a preclinical program for the treatment of Alzheimer's disease. It has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and master collaboration agreement with Bristol Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. Prothena Corporation plc was incorporated in 2012 and is based in Dublin, Ireland.

Latest reported PRTA revenue for 2025-09-30 was $2.4M. Net income was -$36.5M. Revenue was down 45.4% from 2025-06-30 to 2025-09-30. PRTA currently screens at market cap $460.2M.

Use this PRTA page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the PRTA quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the PRTA SEC filings page. Lician reads the product cache first so this HTML stays unique to Prothena Corporation plc even when a live quote feed is slow.